Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
Top Cited Papers
Open Access
- 14 October 2013
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 20 (6), 705-716
- https://doi.org/10.1177/1352458513507821
Abstract
Background: In previous studies, teriflunomide significantly reduced the annualised relapse rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods: Patients with relapsing multiple sclerosis were randomised (1:1:1) to oral teriflunomide 7-or 14mg, or subcutaneous IFNβ-1a 44µg. The primary composite endpoint was time to failure, defined as first occurrence of confirmed relapse or permanent treatment discontinuation for any cause. Secondary endpoints included ARR, Fatigue Impact Scale (FIS) and Treatment Satisfaction Questionnaire for Medication (TSQM). The study was completed 48 weeks after the last patient was randomised. Results: Some 324 patients were randomised (IFNβ-1a: 104; teriflunomide 7 mg: 109; teriflunomide 14 mg: 111). No difference in time to failure was observed. There was no difference in ARR between teriflunomide 14 mg and IFNβ-1a, but ARR was significantly higher with teriflunomide 7 mg. FIS scores indicated more frequent fatigue with IFNβ-1a, though differences were only significant with teriflunomide 7 mg. TSQM scores were significantly higher with teriflunomide. There were no unexpected safety findings. Conclusion: Effects on time to failure were comparable between teriflunomide and IFNβ-1a. There was no difference between teriflunomide 14 mg and IFNβ-1a on ARR, though ARR was higher with teriflunomide 7 mg. The teriflunomide safety profile was consistent with previous studies.This publication has 18 references indexed in Scilit:
- Immune mechanisms of new therapeutic strategies in MS — TeriflunomideClinical Immunology, 2012
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2011
- Fatigue Impact ScaleOccupational Medicine, 2010
- Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisZeitschrift für Neurologie, 2009
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth and Quality of Life Outcomes, 2004
- Leflunomide and malononitriloamidesExpert Opinion on Investigational Drugs, 1997
- A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.Genes & Development, 1996
- Measuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact ScaleClinical Infectious Diseases, 1994
- Rating neurologic impairment in multiple sclerosisNeurology, 1983